A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

As she prepares to change medications for her MS, columnist Leigh Anne Nelson explores the U.S. government’s registry on ...

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

Tolebrutinib is currently being reviewed by the Food and Drug Administration (FDA) for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS). A regulatory decision on the ...

Disease-modifying therapies for MS that prevent brain volume loss are linked to reduced long-term disability, new data show.

Dec 15 () - Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to ​a U. regulatory ...

New research reveals a strong link between persistent brain inflammation and early brain shrinkage in children with MS. These ...

Elsa Mendoza navigates life with multiple sclerosis, using a wheelchair while her son, Fernando, excels as a quarterback ...